Qual é o preço para Zenas BioPharma, Inc. (ZBIO)

O preço para Zenas BioPharma, Inc. (ZBIO) é $33.00

Qual é a capitalização de mercado para Zenas BioPharma, Inc. (ZBIO)

A capitalização de mercado para Zenas BioPharma, Inc. (ZBIO) é $2.08B

Zenas BioPharma, Inc. (ZBIO) Desdobramentos de Ações

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.